Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications

Sujuan Yang, Julie Wang, David Brand, Song Guo Zheng

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF via TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases.

Original languageEnglish (US)
Article number784
JournalFrontiers in immunology
Volume9
Issue numberAPR
DOIs
StatePublished - Apr 19 2018

Fingerprint

Receptors, Tumor Necrosis Factor, Type II
Tumor Necrosis Factor Receptors
Regulatory T-Lymphocytes
Tumor Necrosis Factor-alpha
Therapeutics
Autoimmune Diseases
Regeneration

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications. / Yang, Sujuan; Wang, Julie; Brand, David; Zheng, Song Guo.

In: Frontiers in immunology, Vol. 9, No. APR, 784, 19.04.2018.

Research output: Contribution to journalReview article

@article{16e2855e8a7c419d9efaa9741d4a9e8f,
title = "Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications",
abstract = "Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF via TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases.",
author = "Sujuan Yang and Julie Wang and David Brand and Zheng, {Song Guo}",
year = "2018",
month = "4",
day = "19",
doi = "10.3389/fimmu.2018.00784",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications

AU - Yang, Sujuan

AU - Wang, Julie

AU - Brand, David

AU - Zheng, Song Guo

PY - 2018/4/19

Y1 - 2018/4/19

N2 - Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF via TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases.

AB - Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF via TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=85045744835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045744835&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.00784

DO - 10.3389/fimmu.2018.00784

M3 - Review article

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - APR

M1 - 784

ER -